Related Experiment Video
Updated: Jun 27, 2026
12:33
A Method for Mouse Pancreatic Islet Isolation and Intracellular cAMP Determination
Published on: June 25, 2014
Two drugs converged in a pancreatic β cell
Marissa A Scavuzzo1, Malgorzata Borowiak2
1Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH 44106, USA.
Science Translational Medicine
|February 14, 2020
Summary
This study shows combining a DYRK1A inhibitor with a GLP-1 receptor agonist significantly increases human pancreatic beta cell proliferation. This combination also improves glucose homeostasis in vivo, offering a potential therapeutic strategy.
Area of Science:
- Endocrinology
- Metabolic diseases
- Cell biology
Background:
- Pancreatic beta cells are crucial for glucose regulation.
- Impaired beta cell function contributes to metabolic disorders like type 2 diabetes.
- Current therapies often focus on managing glucose levels rather than restoring beta cell mass.
Purpose of the Study:
- To investigate the synergistic effects of a DYRK1A inhibitor and a GLP-1 receptor agonist on human pancreatic beta cell proliferation.
- To evaluate the impact of this combination therapy on glucose homeostasis in vivo.
Main Methods:
- Utilized a combination of a DYRK1A inhibitor and a GLP-1 receptor agonist.
- Assessed human pancreatic beta cell proliferation.
- Measured glucose homeostasis parameters in vivo.
Main Results:
- The combined treatment significantly boosted human pancreatic beta cell proliferation.
- Improved glucose homeostasis was observed in vivo with the combination therapy.
- DYRK1A inhibition and GLP-1 receptor agonism demonstrated a synergistic effect.
Conclusions:
- Combining a DYRK1A inhibitor and a GLP-1 receptor agonist is a promising strategy for enhancing beta cell regeneration.
- This approach may offer a novel therapeutic avenue for improving glucose control in metabolic diseases.
Related Concept Videos
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...